

Ramot at Tel Aviv University Ltd. and Neurimmune Announce Sponsored Research Agreement for Alzheimer's Disease Treatment

Novel anti-ApoE antibodies to be developed for Alzheimer's disease treatment under a research and options agreement that includes pre-negotiated licensing terms for all ApoE-based products.

Tel Aviv, Israel (July 28 2015) Ramot at Tel Aviv University Ltd., Tel Aviv University's technology transfer company, has signed an agreement with Neurimmune Holding AG to fund the development of a novel approach to treat Alzheimer's disease (AD). The Agreement also includes pre-negotiated licensing terms for future ApoE4-based products.

The aim of the collaboration is to develop anti-Apolipoprotein E4 (ApoE4) antibodies for the treatment of AD and related neurodegenerative diseases. ApoE4 is the most prevalent genetic risk factor for Alzheimer's disease. The incidence of ApoE4 in AD is greater than 50% and increases the risk for the disease by lowering the age of onset by 7 to 9 years. Anti-ApoE4 antibodies are expected to neutralize the toxicity of ApoE4 or to stimulate its removal.

The research by Prof. Daniel Michaelson from the Department of Neurobiology, The George S. Wise Faculty of Life Sciences at Tel Aviv University, focuses on unraveling the basic cellular and molecular mechanisms underlying neurodegeneration in Alzheimer's disease, and the development of novel therapeutic approaches to counteract them.

Neurimmune Holding AG

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapies for the treatment and prevention of neurodegenerative diseases, and other severe diseases with high unmet medical needs. With its unique Reverse Translational Medicine™ platform, Neurimmune develops recombinant human monoclonal antibodies with pharmacological properties and safety profiles closely resembling antibodies occurring in healthy or clinically stable subjects. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy. Neurimmune has partnered four antibody programs with Biogen Idec. The antibody Aducanumab (BIIB037) for Alzheimer's disease is in phase 3 clinical trials. It cleared brain amyloid and halted cognitive decline. BIIB054, a human recombinant monoclonal antibody targeting alpha-synuclein, a target that is believed to play a central role in Parkinson's disease, is in Phase 1. Neurimmune's program packages for amyotrophic lateral sclerosis, fronto-temporal dementia, transthyretin amyloidosis and type-2 diabetes are validated with preclinical proof-of-concept.

For more information regarding Neurimmune, please visit www.neurimmune.com

About Ramot at Tel Aviv University

Ramot is the technology transfer company of Tel Aviv University. Ramot fosters, initiates, leads and manages the transfer of new technologies from university laboratories to the marketplace by performing all activities relating to the protection and commercialization of inventions and discoveries made by faculty, students and other researchers. Ramot provides a dynamic interface connecting industry to leading-edge science and innovation, offering new business opportunities in a broad range of emerging markets .

For more information, visit www.ramot.org.

Company Contact:

Maya Kotler

Marketing Manager

RAMOT at Tel Aviv University Ltd.

E. maya.kotler@ramot.org

P. +972.3.6405062